Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Mallinckrodt
Dow
Johnson and Johnson
Novartis
Chubb
Fuji
Chinese Patent Office
Medtronic
Cipla

Generated: February 21, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,840,737

« Back to Dashboard

Summary for Patent: 5,840,737
Title: Omeprazole solution and method for using same
Abstract:A pharmaceutical composition includes an aqueous solution/suspension of omeprazole or other substituted benzimidazoles and derivatives thereof in a pharmaceutically acceptable carrier comprising a bicarbonate salt of a Group IA metal. A method for treating and/or preventing gastrointestinal conditions by administering to a patient a pharmaceutical composition including an aqueous solution/suspension of omeprazole or other substituted benzimidazoles and derivatives thereof in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal wherein the administering step consists of a single dosage form without requiring further administering of the bicarbonate salt of the Group IA metal. A pharmaceutical composition for making a solution/suspension of omeprazole or other substituted benzimidazoles and derivatives thereof includes omeprazole or other substituted benzimidazoles and derivatives thereof and a bicarbonate salt of a Group IA metal in a form for convenient storage whereby when the composition is dissolved in aqueous solution, the resulting solution is suitable for enteral administration.
Inventor(s): Phillips; Jeffrey Owen (Columbia, MO)
Assignee: The Curators of the University of Missouri (Columbia, MO)
Application Number:08/680,376
Patent Claims: 1. A method for treating gastric acid disorders by administering to a patient a single dose of a pharmaceutical composition of omeprazole or lansoprazole in a pharmaceutically acceptable carrier consisting essentially of a bicarbonate salt of a Group IA metal wherein said administering step consists of providing to the patient orally a single dose of an aqueous solution or, suspension of the pharmaceutical composition without requiring further administration of the bicarbonate salt of the Group IA metal.

2. A method according to claim 1, wherein the Group IA metal is sodium.

3. A method according to claim 1, wherein the Group IA metal is potassium.

4. A method according to claim 1, wherein the concentration of omeprazole in the composition range from approximately 0.5 mg/ml to approximately 6.0 mg/ml.

5. A method according to claim 3, wherein the concentration of omeprazole in said composition range from approximately 1.0 mg/ml to approximately 4.0 mg/ml.

6. A method as set forth in claim 5, wherein the concentration of omeprazole in the composition is approximately 2.0 mg/ml.

7. A method as set forth in claim 1, wherein the concentration of the bicarbonate salt of the Group IA metal in the composition ranges from approximately 5.0% to approximately 60.0%.

8. A method as set forth in claim 7, wherein the concentration of the bicarbonate salt of the Group IA metal in the composition ranges from approximately 7.5% to approximately 10.0%.

9. A method as set forth in claim 8, wherein the concentration of the bicarbonate salt of the Group IA metal is approximately 8.4%.

10. A method as set forth in claim 1, wherein the single dosage form includes a concentration of bicarbonate ranging from approximately 0.75 meq to 1.5 meq per milliliter.

11. A method as set forth in claim 10, wherein the amount of the bicarbonate in the single dosage form is less than approximately 12 mEq/20 mg dose of omeprazole.

12. A method as set forth in claim 1, wherein the single dosage form is administered in a volume of between approximately 10 ml and 20 ml.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Healthtrust
Teva
Express Scripts
Cantor Fitzgerald
Mallinckrodt
Moodys
Chinese Patent Office
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot